Acelyrin, Inc. was a rare success story in this year’s moribund biotech IPO market, raising $540m on the NASDAQ in May in the third-largest biotech flotation since 2018. Investors who piled in at the IPO price of $18 initially did nicely; the shares closed 11 September at $27.90.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?